The Range of Uncertainty: a Tool for Efficiently Addressing Result Variability Around Clinical Decision Points for Hepatitis C Response-guided Therapy

Overview

Journal Biomark Insights

Publisher Sage Publications

Date 2014 May 10

PMID 24812481

Citations 2

Authors

Paul Julicher

Jens Dhein

Affiliations

Soon will be listed here.

Abstract

Despite efforts to standardize molecular diagnostic tests, performance differences are not rare. Laboratories are challenged in situations where treatment rules have been established using a reference assay that is different from the assays being used in daily practice. Assessing the viral load status of patients with chronic hepatitis C under modern triple therapy is a recognized example. We demonstrate the use of the range of uncertainty as an easy and efficient tool that can provide information on the certainty of a test result's interpretation in the context of making hepatitis C virus treatment decisions.

Citing Articles

Multicenter Evaluation of Two Next-Generation HIV-1 Quantitation Assays, Aptima Quant Dx and Cobas 6800, in Comparison to the RealTie HIV-1 Reference Assay.

Wiesmann F, Ehret R, Naeth G, Daumer M, Fuhrmann J, Kaiser R J Clin Microbiol. 2018; 56(10).

PMID: 30068537 PMC: 6156314. DOI: 10.1128/JCM.00292-18.

Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors.

Wiesmann F, Naeth G, Sarrazin C, Berger A, Kaiser R, Ehret R Med Microbiol Immunol. 2014; 204(4):515-25.

PMID: 25398515 PMC: 4514908. DOI: 10.1007/s00430-014-0364-z.

References

Jacobson I, Marcellin P, Zeuzem S, Sulkowski M, Esteban R, Poordad F . Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology. 2012; 56(2):567-75. DOI: 10.1002/hep.25865. View

Panteghini M . Traceability as a unique tool to improve standardization in laboratory medicine. Clin Biochem. 2009; 42(4-5):236-40. DOI: 10.1016/j.clinbiochem.2008.09.098. View

Reitsma J, Rutjes A, Khan K, Coomarasamy A, Bossuyt P . A review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard. J Clin Epidemiol. 2009; 62(8):797-806. DOI: 10.1016/j.jclinepi.2009.02.005. View

Yee H, Chang M, Pocha C, Lim J, Ross D, Morgan T . Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012; 107(5):669-89. DOI: 10.1038/ajg.2012.48. View

Wedemeyer H . Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?. Nat Rev Gastroenterol Hepatol. 2013; 10(2):76-8. DOI: 10.1038/nrgastro.2012.247. View

de Leuw P, Sarrazin C, Zeuzem S . How to use virological tools for the optimal management of chronic hepatitis C. Liver Int. 2011; 31 Suppl 1:3-12. DOI: 10.1111/j.1478-3231.2010.02398.x. View

Wachtel T, Reuben D, Fulton J, Wartman S . The use of the "range of uncertainty". Med Decis Making. 1985; 5(3):325-34. DOI: 10.1177/0272989X8500500308. View

Pauker S, Kassirer J . Therapeutic decision making: a cost-benefit analysis. N Engl J Med. 1975; 293(5):229-34. DOI: 10.1056/NEJM197507312930505. View

Liu S, Cipriano L, Holodniy M, Owens D, Goldhaber-Fiebert J . New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012; 156(4):279-90. PMC: 3586733. DOI: 10.7326/0003-4819-156-4-201202210-00005. View

10.

Ferrante di Ruffano L, Hyde C, McCaffery K, Bossuyt P, Deeks J . Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ. 2012; 344:e686. DOI: 10.1136/bmj.e686. View

11.

Holden M, Madej R, Minor P, Kalman L . Molecular diagnostics: harmonization through reference materials, documentary standards and proficiency testing. Expert Rev Mol Diagn. 2011; 11(7):741-55. DOI: 10.1586/erm.11.50. View

12.

Pisani G, Cristiano K, Marino F, Luciani F, Bisso G, Mele C . Quantification of hepatitis C virus (HCV) RNA in a multicenter study: implications for management of HCV genotype 1-infected patients. J Clin Microbiol. 2009; 47(9):2931-6. PMC: 2738106. DOI: 10.1128/JCM.00532-09. View